Bio-Rad Laboratories Inc Class A
BIO: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$331.00 | Bxdxt | Wfvpclkry |
Narrow-Moat Bio-Rad Reaches New Heights in 2020 Driven by Strong Life Sciences; Shares Overvalued
Narrow-moat Bio-Rad beat our expectations once again in the fourth quarter, driven by growth in life sciences, an improved margin and further gains related to the Sartorius investment. While we may marginally increase our fair value estimate after incorporating full-year results for the firm and the impact of continued strong results from Sartorius, we continue to view shares as overvalued.